

**Editor**

Tore K Kvien

**Associate Editors**

Francis Berenbaum  
Johannes Bijlsma  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes  
David Pisetsky

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 12.384

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2016 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Nova Techset Private Limited, Bengaluru & Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 1741** Predicting improvement in diffuse scleroderma: lessons learnt  
*J E Pope*

**Clinical and epidemiological research**

- 1743** Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis  
*R Dobrota, B Maurer, N Graf, S Jordan, C Mihai, O Kowal-Bielecka, Y Allano, O Distler, on behalf of EUSTAR coauthors*
- 1749** Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged women  
*S Kluzek, M T Sanchez-Santos, K M Leyland, A Judge, T D Spector, D Hart, C Cooper, J Newton, N K Arden*
- 1757** Increased pretreatment serum IFN- $\beta/\alpha$  ratio predicts non-response to tumour necrosis factor  $\alpha$  inhibition in rheumatoid arthritis  
*T W Muskardin, P Vashisht, J M Dorschner, M A Jensen, B S Chrobot, M Kern, J R Curtis, M I Danila, S S Cofield, N Shadick, P A Nigrovic, E W St Clair, C O Bingham III, R Furie, W Robinson, M Genovese, C C Striebich, J R O'Dell, G M Thiele, L W Moreland, M Levesque, S L Bridges Jr, P K Gregersen, T B Niewold*
- 1763** Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study  
*M A D'Agostino, R J Wakefield, H Berner-Hammer, O Vittecoq, G Filippou, P Balint, I Möller, A Iagnocco, E Naredo, M Østergaard, M Boers, C Gaillez, K V Holder, M Le Bars, on behalf of the OMERACT-EULAR-Ultrasound Task Force*
- 1770** Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry  
*M Matucci-Cerinic, T Krieg, L Guillemin, B Schwirier, D Rosenberg, P Cornelisse, C P Denton*
- 1777** Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUALDIC study  
*D Saadoun, V Thibault, S N Si Ahmed, L Alric, M Mallet, C Guillaud, H Izzedine, A Plaisier, H Fontaine, M Costopoulos, M Le Garff-Tavernier, C Hezode, S Pol, L Musset, T Poinard, P Cacoub*
- 1783** Signal intensity alteration in the infrapatellar fat pad at baseline for the prediction of knee symptoms and structure in older adults: a cohort study  
*W Han, D Aitken, Z Zhu, A Halliday, X Wang, B Antony, F Cicuttini, G Jones, C Ding*
- 1789** How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries  
*J Askling, N Berglind, S Franzen, T Frisell, C Garwood, J D Greenberg, M Ho, M Holmqvist, L Horne, E Inoue, K Michaud, F Nyberg, D A Pappas, G Reed, E Tanaka, T N Tran, S M M Verstappen, H Yamanaka, E Wesby-van Swaay, D Symmons*
- 1797** Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease  
*K Michaud, N Berglind, S Franzen, T Frisell, C Garwood, J D Greenberg, M Ho, M Holmqvist, L Horne, E Inoue, F Nyberg, D A Pappas, G Reed, D Symmons, E Tanaka, T N Tran, S M M Verstappen, E Wesby-van Swaay, H Yamanaka, J Askling*

- 1806** Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis  
*C Gabay, I B McInnes, A Kavanaugh, K Tuckwell, M Kleerman, J Pulley, N Sattar*
- 1813** Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis  
*J Zhang, F Xie, H Yun, L Chen, P Muntner, E B Levitan, M M Safford, S T Kent, M T Osterman, J D Lewis, K Saag, J A Singh, J R Curtis*
- 1819** Prevalence of ultrasound synovial inflammatory findings in healthy subjects  
*I Padovano, F Costantino, M Breban, M A D'Agostino*
- 1824** Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis  
*H W van Steenberghe, L Mangnus, M Reijnen, T W J Huijzinga, A H M van der Helm-van Mil*
- 1831** Parental rheumatoid arthritis and long-term child morbidity: a nationwide cohort study  
*A L Rom, C S Wu, J Olsen, D Jawaheer, M L Heiland, B Ottesen, L S Mørch*
- 1838** Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study  
*G L Jakobsson, O Stephansson, J Askling, L T H Jacobsson*
- 1843** Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis  
*J R Curtis, F Xie, H Yun, S Bernatsky, K L Winthrop*
- 1848** Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy  
*F M van der Valle, S J B Moens, S L Verweij, A C Strang, A J Nederveen, H J Verberne, M T Nurmohamed, D L Baeten, E S G Stros*
- 1852** Osteoarthritic bone marrow lesions almost exclusively colocalize with denuded cartilage: a 3D study using data from the Osteoarthritis Initiative  
*M A Bowes, S W D McLure, C B H Wolstenholme, G R Vincent, S Williams, A Grainger, P G Conaghan*

**MORE CONTENTS ►**

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme.  
See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

COPE

Member since 2008

JMD0008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it



The online version of this article contains multiple choice questions hosted on BMJ Learning.

## Basic and translational research

**1858** Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells

*A Yoshizaki, T Taniguchi, R Saigusa, T Fukasawa, S Ebata, H Numajiri, K Nakamura, T Yamashita, T Takahashi, T Toyama, Y Asano, T F Tedder, S Sato*

**1866** Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs

 OPEN ACCESS

*E Corsiero, M Bombardieri, E Carlotti, F Pratesi, W Robinson, P Migliorini, C Pitzalis*

**1876** Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis

 OPEN ACCESS

*A Schweszer, X Jiang, T R Mikuls, J B Payne, H R Sayles, A-M Quirke, B M Kessler, R Fischer, P J Venables, K Lundberg, K S Midwood*

**1884** T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals

 OPEN ACCESS

*L Hunt, E M Hensor, J Nam, A N Burska, R Parmar, P Emery, F Ponchel*

**1891** Protective effect of HLA-DRB1\*13 alleles during specific phases in the development of ACPA-positive RA

*J van Heemst, A H Hensvold, X Jiang, H van Steenberg, L Klareskog, T W J Huizinga, A van der Helm-van Mil, A I Catrina, R E M Toes, K Lundberg, D van der Woude*

## Electronic pages

### Correspondence

**e62** Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description

*F Meacci, M Manfredi, M Infantino, V Grossi, M Benucci*

**e63** Response to: 'Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRA main and extension studies: utility of laboratory methods description' by Francesca Meacci *et al*

*J Braun*

**e64** Difference between Enbrel and Benepali treatment groups in 'hepatobiliary disorders'

*M Scheinberg, V Azevedo*

**e65** Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo

*P Emery, J Vencovsky, J Chil, S Y Cheong, Y H Rho*

**e66** The role of infrapatellar fat pad resection in total knee arthroplasty

*L D White, T M Melhuish*

**e67** Response to: 'The role of infrapatellar fat pad resection in total knee arthroplasty' by White *et al*

*W Han, F Pan, Z Liu, Z Zhu, X Wang, S Zheng, B Antony, C Ding*

**e68** Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!

*M Boers*

**e69** Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers

*P Emery, C O Bingham III, G R Burmester, V P Bykerk, D E Furst, X Mariette, D van der Heijde, R van Vollenhoven, C Arendt, I Mountian, O Purcaru, D Taita, B VanLunen, M E Weinblatt*

**e70** Denosumab, cortical bone and bone erosions in rheumatoid arthritis

*M Rossini, G Adami, O Viapiana, L Idolazzi, D Gatti*

**e71** Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini *et al*

*T Takeuchi, Y Tanaka, N Ishiguro, H Yamanaka, T Yoneda, T Ohira, N Okubo, H K Genant, D van der Heijde*